ESMO 2024: Combination of luveltamab tazevibulin + bevacizumab Shows Positive Outcomes in Phase 1b Study for Patients with Ovarian Cancer

Folate receptor alpha or FRα, is a glycosylphosphatidylinositol (GPI-) linked cell-surface glycoprotein which binds and internalizes folic acid to support DNA and RNA synthesis during cell proliferation. Although FolRα is normally expressed at low levels on the luminal surface of a small number of organs, high levels of FolRα have been observed in several malignancies, including, but not limited to, ovarian cancer and endometrial cancer.

Authors

Publication Details

Journal
ADC Review / Journal of Antibody-drug Conjugates
Published
2024-09-16
DOI
https://doi.org/10.14229/jadc.2024.09.16.004
Primary Topic
Ovarian cancer diagnosis and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ESMO 2024: Combination of luveltamab tazevibulin + bevacizumab Shows Positive Outcomes in Phase 1b Study for Patients with Ovarian Cancer

Peter Hofland
ADC Review / Journal of Antibody-drug Conjugates
Ovarian cancer diagnosis and treatment
article

ESMO 2024: Combination of luveltamab tazevibulin + bevacizumab Shows Positive Outcomes in Phase 1b Study for Patients with Ovarian Cancer

Peter Hofland
article en

Abstract

Folate receptor alpha or FRα, is a glycosylphosphatidylinositol (GPI-) linked cell-surface glycoprotein which binds and internalizes folic acid to support DNA and RNA synthesis during cell proliferation. Although FolRα is normally expressed at low levels on the luminal surface of a small number of organs, high levels of FolRα have been observed in several malignancies, including, but not limited to, ovarian cancer and endometrial cancer.

ADC Review / Journal of Antibody-drug Conjugates
Openalex Percentile: Top 77%
Ovarian cancer diagnosis and treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

ESMO 2024: Combination of luveltamab tazevibulin + bevacizumab Shows Positive Outcomes in Phase 1b Study for Patients with Ovarian Cancer — Peter Hofland · ADC Review / Journal of Antibody-drug Conjugates (2024) | TGRS Research Map | TGRS